A modified chorioallantoic membrane assay allows for specific detection of endothelial apoptosis induced by antiangiogenic substances

被引:22
作者
Mauricio González-Iriarte
Rita Carmona
José María Pérez-Pomares
David Macías
Miguel Ángel Medina
Ana R. Quesada
Ramón Muñoz-Chápuli
机构
[1] Department of Animal Biology, University of Málaga, Málaga
[2] Dept. of Molec. Biol. and Biochem., University of Málaga, Málaga
[3] Department of Animal Biology, Faculty of Science, University of Málaga
关键词
Aeroplysinin-1; Angiogenesis; Apoptosis; Camptothecin; Chorioallantoic membrane assay; Endothelium; TUNEL assay;
D O I
10.1023/B:AGEN.0000021388.59617.6b
中图分类号
学科分类号
摘要
Current in vivo angiogenesis assays allow for the assessment of vascular growth inhibition induced by a test substance, but they usually do not provide information about the mechanisms underlying such an inhibition. A potential antiangiogenic mechanism is the triggering of endothelial apoptosis in the growing vessels. Apoptogenic substances can be of interest for antiangiogenic therapy specially if they specifically perform their action on the angiogenic endothelium. We have developed a modification of the chorioallantoic membrane (CAM) assay using embryos of quail (Coturnix coturnix japonica). This novel assay allows to elucidate whether an antiangiogenic substance is specifically triggering an apoptotic response in endothelial cells. We have used a quail-specific monoclonal endothelial marker (QH1), a standard TUNEL technique of apoptotic cell labelling together with a general nuclear counterstaining with propidium iodide. Through laser confocal microscopy, paraffin sections of chorioallantoic membranes treated with test substances are stained in three colours: red for normal cell nuclei, yellow-green for apoptotic nuclei and blue for endothelial cells and endothelial progenitors. In a test experience, our assay showed significant differences in the apoptogenic properties of two antiangiogenic substances, camptothecin and aeroplysinin-1.
引用
收藏
页码:251 / 254
页数:3
相关论文
共 17 条
[1]  
Folkman J., Angiogenesis in cancer, vascular rheumatoid and other disease, Nat Med, 1, pp. 27-31, (1995)
[2]  
Kerbel R., Folkman J., Clinical translation of angiogenesis inhibitors, Nature Rev Cancer, 2, pp. 727-739, (2002)
[3]  
Jain R.K., Schlenger K., Hockel M., Yuan F., Quantitative angiogenesis assays: Progress and problems, Nat Med, 3, pp. 1203-1208, (1997)
[4]  
Auerbach R., Lewis R., Shinners B., Et al., Angiogenesis assays: A critical overview, Clin Chem, 49, pp. 32-40, (2003)
[5]  
Parsons-Wingerter P., Lwai B., Yang M.C., Et al., A novel assay of angiogenesis in the quail chorioallantoic membrane: Stimulation by bFGF and inhibition by angiostatin according to fractal dimension and grid intersection, Microvasc Res, 55, pp. 201-214, (1998)
[6]  
Oh S.J., Jeltsch M.M., Birkenhager R., Et al., VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane, Dev Biol, 188, pp. 96-109, (1997)
[7]  
Pardanaud L., Altmann C., Kitos P., Et al., Vasculogenesis in the early quail blastodisc as studied with a monoclonal antibody recognizing endothelial cells, Development, 100, pp. 339-349, (1987)
[8]  
Kollmannsberger C., Mross K., Jakob A., Et al., Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience, Oncology, 56, 1, pp. 1-12, (1999)
[9]  
Kaufmann S.H., Cell death induced by topoisomerase-targeted drugs: More questions than answers, Biochim Biophys Acta, 1400, pp. 195-211, (1998)
[10]  
Jung L.L., Zamboni W.C., Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: Can we improve it?, Drug Resist Update, 4, pp. 273-288, (2001)